The pre-commercial company is looking to take on a $23 billion industry leader. Promising late-stage clinical results suggest it may have a shot.
News & Analysis: Apellis Pharmaceuticals, Inc.
The company's lead drug candidate bested a competitor's therapy on a key endpoint in a phase 3 trial.
Pegcetacoplan is the first drug to beat Soliris in improving hemoglobin levels in PNH patients.
It looks like Apellis could have another competitor.
Keeping up with the news from major medical meetings has become a requirement for healthcare investors.
The company is issuing convertible debt to pad its balance sheet and fund late-stage clinical trials.
Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.
There are good reasons these stocks missed out on the rally.